{"preliminary_commentary":{"by_channel":{"youtube":75,"x_thread":71,"podcast":33,"x_video":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04934475\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"MIDAS","nct_id":"NCT04934475","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=midas-nct04934475. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"MIDAS","arms":[{"description":"Arm A: consolidation with 6 additional cycles of Isa-KRD (cycles 7 to 12; 28-day cycle; Isa-KRD = Isatuximab Carfilzomib Lenalidomide Dexamethasone):\n\n* Isatuximab: 10 mg/kg I.V. on days 1 and 15 (cycles 7 to 12)\n* Carfilzomib: 56 mg/m2 I.V on days 1, 8 and 15 (cycles 7 to 12)\n* Lenalidomide: 25 mg per day orally from days 1 to 21\n* Dexamethasone: 40 mg orally on day 1, 8, 15, 22","label":"MRD Standard-risk patients (post induction MRD <10-5, MRD SR) (1:1 Randomization) : Arm A","type":"EXPERIMENTAL"},{"description":"Arm B: consolidation with ASCT followed by 2 cycles of Isa-KRD (cycles 7 and 8; Isa-KRD = Isatuximab Carfilzomib Lenalidomide Dexamethasone; 28-day cycle) Melphalan 200 mg/m2 followed by autologous stem cell transplantation (please refer to section 6.3.2)\n\n* Isatuximab: 10 mg/kg I.V. on days 1 and 15 (cycles 7 to 8)\n* Carfilzomib: 56 mg/m2 I.V on days on days 1, 8 and 15 (cycles 7 to 8)\n* Lenalidomide: 25 mg per day orally from days 1 to 21\n* Dexamethasone: 40 mg orally on days 1, 8, 15, 22 (cycles 7 to 8)","label":"MRD Standard-risk patients (post induction MRD <10-5, MRD SR) (1:1 Randomization): Arm B","type":"EXPERIMENTAL"},{"description":"Arm C: ASCT followed by 2 cycles of Isa-KRD (cycles 7 and 8; Isa-KRD = Isatuximab Carfilzomib Lenalidomide Dexamethasone; 28-day cycle) Melphalan 200 mg/m2 followed by autologous stem cell transplantation.\n\n* Isatuximab: 10 mg/kg I.V. on days 1 and 15 (cycles 7 to 8)\n* Carfilzomib: 56 mg/m2 I.V on days on days 1, 8 and 15 (cycle 7 to 8)\n* Lenalidomide: 25 mg per day orally from day 1 to day 21\n* Dexamethasone: 40 mg orally on days 1, 8, 15, 22 (cycle 7 to 8)","label":"MRD High-risk patients (post induction MRD >10-5, MRD HR) (1:1 Randomization): Arm C","type":"EXPERIMENTAL"},{"description":"Tandem ASCT Melphalan 200 mg/m2 followed by autologous stem cell transplantation.","label":"MRD High-risk patients (post induction MRD >10-5, MRD HR) (1:1 Randomization): Arm D","type":"EXPERIMENTAL"}],"collaborators":["Amgen","Sanofi","Bristol-Myers Squibb"],"completion_date":{"date":"2028-09-30","type":"ESTIMATED"},"conditions":["Multiple Myeloma"],"enrollment":{"count":791,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Isatuximab","otherNames":["Carfilzomib","Revlimid","Dexamethasone"],"type":"DRUG"},{"name":"ASCT","otherNames":[],"type":"PROCEDURE"}],"last_update":"2024-11-07","lead_sponsor":"Intergroupe Francophone du Myelome","official_title":"MInimal Residual Disease Adapted Strategy: Frontline Therapy for Patients Eligible for Autologous Stem Cell Transplantation Less Than 66 Years; a Prospective Study","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2024-09-30","type":"ACTUAL"},"primary_outcomes":[{"measure":"Negative MRD rate","timeFrame":"Time Frame: change from post induction baseline MRD at end of consolidation phase (6 months)"},{"measure":"Negative MRD rate","timeFrame":"change from post induction baseline MRD at 1 years"},{"measure":"Negative MRD rate","timeFrame":"change from post induction baseline MRD at 2 years"},{"measure":"Negative MRD rate","timeFrame":"change from post induction baseline MRD at 3 years"}],"references":[{"citation":"Magrangeas F, Cherkaoui M, Bessonneau-Gaborit V, Derrien J, Chevalier C, Guerin-Charbonnel C, Diamond B, Samur MK; Intergroupe Francophone du Myelome (IFM); Hulin C, Caillot D, Karlin L, Arnulf B, Landgren O, Munshi NC, Avet-Loiseau H, Martinet L, Corre J, Perrot A, Moreau P, Touzeau C, Minvielle S, Letouze E. Molecular predictors of minimal residual disease in newly diagnosed multiple myeloma treated with quadruplet therapy. Nat Med. 2026 Oct 19. doi: 10.1038/s41591-026-04692-0. Online ahead of print.","pmid":"42897348","type":"DERIVED"},{"citation":"Perrot A, Lambert J, Hulin C, Pieragostini A, Karlin L, Arnulf B, Rey P, Garderet L, Macro M, Escoffre-Barbe M, Gay J, Chalopin T, Gounot R, Schiano JM, Mohty M, Leleu X, Manier S, Mariette C, Chaleteix C, Braun T, De Prijck B, Avet-Loiseau H, Mary JY, Corre J, Moreau P, Touzeau C; MIDAS Study Group. Measurable Residual Disease-Guided Therapy in Newly Diagnosed Myeloma. N Engl J Med. 2025 Jul 31;393(5):425-437. doi: 10.1056/NEJMoa2505133. Epub 2025 Jun 3.","pmid":"40459097","type":"DERIVED"},{"citation":"Perrot A, Touzeau C, Lambert J, Hulin C, Caillot D, Karlin L, Arnulf B, Rey P, Garderet L, Macro M, Escoffre Barbe M, Gay J, Chalopin T, Gounot R, Schiano JM, Tiab M, Mohty M, Kuhnowski F, Fontan J, Manier S, Orsini-Piocelle F, Vincent L, Rigaudeau S, Leleu X, Hebraud B, Flet L, Malfuson JV, Jacquet C, Chaoui D, Meuleman N, Abarah W, Montes L, Benramdane R, Sonntag C, Zerazhi H, Danu A, Allangba O, Dib M, Roussel M, Cereja S, Depaus J, Branche N, Demarquette H, Richez V, Cherel B, Frenzel L, Vekemans MC, Bigot N, Avet-Loiseau H, Corre J, Moreau P. Isatuximab, carfilzomib, lenalidomide, and dexamethasone induction in newly diagnosed myeloma: analysis of the MIDAS trial. Blood. 2025 Jul 3;146(1):52-61. doi: 10.1182/blood.2024026230.","pmid":"39841461","type":"DERIVED"},{"citation":"Mohan M, Gundarlapalli S, Szabo A, Yarlagadda N, Kakadia S, Konda M, Jillella A, Fnu A, Ogunsesan Y, Yarlagadda L, Thalambedu N, Munawar H, Graziutti M, Al Hadidi S, Alapat D, Thanendrarajan S, Zangari M, van Rhee F, Schinke C. Tandem autologous stem cell transplantation in patients with persistent bone marrow minimal residual disease after first transplantation in multiple myeloma. Am J Hematol. 2022 Jun 1;97(6):E195-E198. doi: 10.1002/ajh.26530. Epub 2022 Mar 21. No abstract available.","pmid":"35285981","type":"DERIVED"}],"start_date":{"date":"2021-12-08","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"MInimal Residual Disease Adapted Strategy","url":"https://clinicaltrials.gov/study/NCT04934475"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/midas-nct04934475"}